JP2022515487A5 - - Google Patents

Info

Publication number
JP2022515487A5
JP2022515487A5 JP2021537771A JP2021537771A JP2022515487A5 JP 2022515487 A5 JP2022515487 A5 JP 2022515487A5 JP 2021537771 A JP2021537771 A JP 2021537771A JP 2021537771 A JP2021537771 A JP 2021537771A JP 2022515487 A5 JP2022515487 A5 JP 2022515487A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequences
sequence numbers
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/129017 external-priority patent/WO2020135674A1/en
Publication of JP2022515487A publication Critical patent/JP2022515487A/ja
Publication of JP2022515487A5 publication Critical patent/JP2022515487A5/ja
Priority to JP2024103100A priority Critical patent/JP7724332B2/ja
Pending legal-status Critical Current

Links

JP2021537771A 2018-12-28 2019-12-27 クローディン18.2結合部分およびその利用 Pending JP2022515487A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103100A JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン18.2結合部分およびその利用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CNPCT/CN2018/125052 2018-12-28
CNPCT/CN2019/095827 2019-07-12
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103100A Division JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン18.2結合部分およびその利用

Publications (2)

Publication Number Publication Date
JP2022515487A JP2022515487A (ja) 2022-02-18
JP2022515487A5 true JP2022515487A5 (cg-RX-API-DMAC7.html) 2022-11-24

Family

ID=71127698

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021537771A Pending JP2022515487A (ja) 2018-12-28 2019-12-27 クローディン18.2結合部分およびその利用
JP2024103100A Active JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン18.2結合部分およびその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103100A Active JP7724332B2 (ja) 2018-12-28 2024-06-26 クローディン18.2結合部分およびその利用

Country Status (12)

Country Link
US (1) US12258418B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902839A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022515487A (cg-RX-API-DMAC7.html)
KR (1) KR20210110339A (cg-RX-API-DMAC7.html)
CN (1) CN113227146B (cg-RX-API-DMAC7.html)
AU (1) AU2019415848B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012608A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125193A1 (cg-RX-API-DMAC7.html)
IL (1) IL284393A (cg-RX-API-DMAC7.html)
MX (1) MX2021007939A (cg-RX-API-DMAC7.html)
SG (1) SG11202106534RA (cg-RX-API-DMAC7.html)
WO (1) WO2020135674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023024A2 (pt) * 2019-05-16 2022-01-25 Qilu Pharmaceutical Co Ltd Anticorpo contra claudina 18a2 e uso do mesmo
AU2020378502A1 (en) 2019-11-05 2022-06-16 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
CN114829408B (zh) 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体,抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
KR20230113578A (ko) * 2020-11-27 2023-07-31 선샤인 레이크 파르마 컴퍼니 리미티드 Cldn18.2 항체 및 그의 용도
CN114539402B (zh) * 2020-11-27 2025-06-13 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN116940598A (zh) * 2021-02-08 2023-10-24 山东博安生物技术股份有限公司 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
EP4335873A4 (en) * 2021-05-08 2025-03-19 RemeGen Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
WO2023167564A1 (ko) 2022-03-04 2023-09-07 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
AU2023371764A1 (en) 2022-11-01 2025-05-15 AbTis Co., Ltd. Compound comprising fc-binding unit, and conjugate prepared using same
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用
WO2025038602A1 (en) * 2023-08-14 2025-02-20 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
WO2025072299A1 (en) * 2023-09-25 2025-04-03 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
WO2025251228A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Cldn18.2-targeting chimeric antigen receptor and engineered cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN120329449A (zh) * 2014-07-17 2025-07-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
JP7840511B2 (ja) * 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN114630840B (zh) * 2019-08-20 2024-08-02 苏州创胜医药集团有限公司 新型抗cldn18.2抗体

Similar Documents

Publication Publication Date Title
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2021522801A5 (cg-RX-API-DMAC7.html)
JP2023543031A5 (cg-RX-API-DMAC7.html)
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2020062036A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2024125370A (ja) クローディン18.2結合部分およびその利用
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2018035138A5 (cg-RX-API-DMAC7.html)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2019533719A5 (cg-RX-API-DMAC7.html)
JP2015163068A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2025092589A5 (cg-RX-API-DMAC7.html)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
JP2010509931A5 (cg-RX-API-DMAC7.html)
WO2008004834A1 (en) Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2020522488A5 (cg-RX-API-DMAC7.html)
US20250136720A1 (en) Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)